Tevogen is a Warren, New Jersey allogeneic T-cell company that has already run its only human study and has now told investors it does not start another trial until fresh capital arrives. That pause, not the Phase One safety print, is the quarter's real event. The equity is a residual claim on a platform whose next clinical step is explicitly unfunded, while day-to-day operations continue on a related-party line of credit and an affiliated grant commitment. The latest reported quarter ended June 30, 2026. What looks like a cell-therapy listing is, for now, a family-financed holding pattern around a completed proof-of-concept study.
Cash at mid-year sat just above $1 million against a first-half net loss above eleven million. Survival therefore depends on The Patel Family, LLP remaining willing to advance the unused portion of its unsecured facility and on KRHP LLC delivering the rest of a seven million grant. Polar Multi-Strategy Master Fund still holds defaulted merger notes that were due within days of the de-SPAC close. A one-for-fifty reverse split in March restored the bid-price listing test, but it did not restore a third-party cost of capital.
Nasdaq closed the public-float deficiency in September after freely held shares cleared the fifteen million bar. The fifty million listed-securities test still has an October deadline, and the equity now trades near that line. The share last changed hands near $8. The question the next two quarters resolve is whether a partnership or an unaffiliated raise funds a study of the lead candidate in immunocompromised COVID patients, or whether the company remains a family-financed listing with a frozen pipeline.